Robert H. Sinnamon

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

Alastair J. King, Marc R. Arnone, Maureen R. Bleam et al. · PLoS ONE · 2013 · 217 citations · Full text

Medicine, Oncology, Pharmacology +16

Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction

Aidan G. Gilmartin, Thomas Faitg, Mark C. Richter et al. · Nature Chemical Biology · 2014 · 208 citations

Life Sciences, Biochemistry, Molecular Biology +14

Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation

Glenn S. Van Aller, Nicolas Reynoird, Olena Barbash et al. · Epigenetics · 2012 · 174 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +17

Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase

Jeffrey D. Carson, Glenn Van Aller, Ruth Lehr et al. · Biochemical Journal · 2007 · 119 citations

Life Sciences, Molecular Biology, Oncology +17

A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues

Lata T. Gooljarsingh, Christine Fernandes, Kang Yan et al. · Proceedings of the National Academy of Sciences · 2006 · 119 citations

Medicine, Medicinal Chemistry, Pharmacology +13